Cargando…
COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed
Management and dose adjustment are a major concern for clinicians in the absence of specific clinical outcome data for patients on antiepileptic drugs (AEDs), in the event of short-term (5 days) nirmatrelvir/ritonavir co-exposure. Therefore, in this report, we identified drugs that require dose adju...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362546/ https://www.ncbi.nlm.nih.gov/pubmed/35930055 http://dx.doi.org/10.1007/s00228-022-03370-7 |
_version_ | 1784764743401078784 |
---|---|
author | Yalcin, Nadir Allegaert, Karel |
author_facet | Yalcin, Nadir Allegaert, Karel |
author_sort | Yalcin, Nadir |
collection | PubMed |
description | Management and dose adjustment are a major concern for clinicians in the absence of specific clinical outcome data for patients on antiepileptic drugs (AEDs), in the event of short-term (5 days) nirmatrelvir/ritonavir co-exposure. Therefore, in this report, we identified drugs that require dose adjustment because of drug-drug interactions (DDIs) between nirmatrelvir/ritonavir and AEDs. We hereby used four databases (Micromedex Drug Interaction, Liverpool Drug Interaction Group for COVID-19 Therapies, Medscape Drug Interaction Checker, and Lexicomp Drug Interactions) and DDI-Predictor. In the light of applying the DDI-Predictor, for carbamazepine, clobazam, oxcarbazepine, eslicarbazepine, phenytoin, phenobarbital, pentobarbital, rufinamide, and valproate as CYP3A4 inducers, we recommend that a dose adjustment of short-term nirmatrelvir/ritonavir as a substrate (victim) drug would be more appropriate instead of these AEDs to avoid impending DDI-related threats in patients with epilepsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00228-022-03370-7. |
format | Online Article Text |
id | pubmed-9362546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-93625462022-08-10 COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed Yalcin, Nadir Allegaert, Karel Eur J Clin Pharmacol Perspective Management and dose adjustment are a major concern for clinicians in the absence of specific clinical outcome data for patients on antiepileptic drugs (AEDs), in the event of short-term (5 days) nirmatrelvir/ritonavir co-exposure. Therefore, in this report, we identified drugs that require dose adjustment because of drug-drug interactions (DDIs) between nirmatrelvir/ritonavir and AEDs. We hereby used four databases (Micromedex Drug Interaction, Liverpool Drug Interaction Group for COVID-19 Therapies, Medscape Drug Interaction Checker, and Lexicomp Drug Interactions) and DDI-Predictor. In the light of applying the DDI-Predictor, for carbamazepine, clobazam, oxcarbazepine, eslicarbazepine, phenytoin, phenobarbital, pentobarbital, rufinamide, and valproate as CYP3A4 inducers, we recommend that a dose adjustment of short-term nirmatrelvir/ritonavir as a substrate (victim) drug would be more appropriate instead of these AEDs to avoid impending DDI-related threats in patients with epilepsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00228-022-03370-7. Springer Berlin Heidelberg 2022-08-05 2022 /pmc/articles/PMC9362546/ /pubmed/35930055 http://dx.doi.org/10.1007/s00228-022-03370-7 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Perspective Yalcin, Nadir Allegaert, Karel COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
title | COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
title_full | COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
title_fullStr | COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
title_full_unstemmed | COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
title_short | COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
title_sort | covid-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362546/ https://www.ncbi.nlm.nih.gov/pubmed/35930055 http://dx.doi.org/10.1007/s00228-022-03370-7 |
work_keys_str_mv | AT yalcinnadir covid19andantiepilepticdrugsanapproachtoguidepracticeswhennirmatrelvirritonaviriscoprescribed AT allegaertkarel covid19andantiepilepticdrugsanapproachtoguidepracticeswhennirmatrelvirritonaviriscoprescribed |